Postpartum Depression – Pipeline Insight, 2020

55 Pages - DELVE15186

DelveInsight’s, “Postpartum Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Postpartum Depression Understanding
Postpartum Depression: Overview
The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. Most new moms experience postpartum "baby blues" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues typically begin within the first two to three days after delivery, and may last for up to two weeks. But some new moms experience a more severe, long-lasting form of depression known as postpartum depression. Rarely, an extreme mood disorder called postpartum psychosis also may develop after childbirth. Postpartum depression isn't a character flaw or a weakness. Sometimes it's simply a complication of giving birth.
Signs and symptoms of depression after childbirth vary, and they can range from mild to severe.
• Baby blues symptoms
1. Mood swings
2. Anxiety
3. Sadness
4. Irritability
5. Feeling overwhelmed
6. Crying
7. Reduced concentration
8. Appetite problems
9. Trouble sleeping
• Postpartum depression signs and symptoms may include:
1. Depressed mood or severe mood swings
2. Excessive crying
3. Difficulty bonding with your baby
4. Withdrawing from family and friends
5. Loss of appetite or eating much more than usual
6. Inability to sleep (insomnia) or sleeping too much
7. Overwhelming fatigue or loss of energy
8. Reduced interest and pleasure in activities you used to enjoy
9. Intense irritability and anger
10. Fear that you're not a good mother
11. Hopelessness
12. Feelings of worthlessness, shame, guilt or inadequacy
13. Diminished ability to think clearly, concentrate or make decisions
14. Restlessness
15. Severe anxiety and panic attacks
16. Thoughts of harming yourself or your baby
17. Recurrent thoughts of death or suicide
As part of evaluation, doctor may:
• Do a depression screening that may include having fill out a questionnaire
• Order blood tests to determine whether an underactive thyroid is contributing to signs and symptoms
• Order other tests, if warranted, to rule out other causes for the symptoms
There are two main treatments for postpartum depression: medication and therapy. Either one can be used alone, but they may be more effective when used together. It’s also important to make some healthy choices in daily routine.
• Medication: Antidepressants have a direct effect on the brain. They alter the chemicals that regulate mood. They won’t work right away, though. It can take several weeks of taking the medication before the patients notice a difference in mood.
• Therapy: A psychiatrist, psychologist, or other mental health professional can provide counseling. Therapy can help make sense of destructive thoughts and offer strategies for working through them.
Postpartum Depression Emerging Drugs Chapters
This segment of the Postpartum Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postpartum Depression Emerging Drugs
• Zuranolone: Sage Therapeutics
Sage Therapeutics is conducting a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of SAGE-217 in the treatment of adults with severe postpartum depression. The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Further product details are provided in the report……..
Postpartum Depression: Therapeutic Assessment
This segment of the report provides insights about the different Postpartum Depression drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Postpartum Depression
There are approx. 2+ key companies which are developing the therapies for Postpartum Depression. The companies which have their Postpartum Depression drug candidates in the mid to advanced stage, i.e. phase III include, Sage Therapeutics and others.
DelveInsight’s report covers around 2+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postpartum Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postpartum Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postpartum Depression drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression R&D. The therapies under development are focused on novel approaches to treat/improve Postpartum Depression.
Postpartum Depression Report Insights
• Postpartum Depression Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Postpartum Depression Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Postpartum Depression drugs?
• How many Postpartum Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postpartum Depression?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postpartum Depression and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Sage Therapeutics
• Epharmix, Inc.
Key Products
• SAGE-217
• Epharmix


Executive Summary
Postpartum Depression: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Postpartum Depression – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Postpartum Depression companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Postpartum Depression Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
SAGE-217: Sage Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Postpartum Depression Key Companies
Postpartum Depression Key Products
Postpartum Depression- Unmet Needs
Postpartum Depression- Market Drivers and Barriers
Postpartum Depression- Future Perspectives and Conclusion
Postpartum Depression Analyst Views
Postpartum Depression Key Companies

Table 1 Total Products for Postpartum Depression
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

Figure 1 Total Products for Postpartum Depression
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838


Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838


Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838